Back to User profile » Dr James A. Kaye

Papers published by Dr James A. Kaye:


Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Arana A, Pottegård A, Kuiper JG, Booth H, Reutfors J, Calingaert B, Lund LC, Crellin E, Schmitt-Egenolf M, Kaye JA, Gembert K, Rothman KJ, Kieler H, Dedman D, Houben E, Gutiérrez L, Hallas J, Perez-Gutthann S

Clinical Epidemiology 2021, 13:1141-1153

Published Date: 29 December 2021

US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma

Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J

ClinicoEconomics and Outcomes Research 2020, 12:317-325

Published Date: 19 June 2020

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET

Lung Cancer: Targets and Therapy 2019, 10:11-20

Published Date: 8 February 2019

A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study)

Castellsague J, Kuiper JG, Pottegård A, Anveden Berglind I, Dedman D, Gutierrez L, Calingaert B, van Herk-Sukel MP, Hallas J, Sundström A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S

Clinical Epidemiology 2018, 10:299-310

Published Date: 13 March 2018

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology

Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C

OncoTargets and Therapy 2012, 5:287-296

Published Date: 23 October 2012